Roche's Genentech Expands U.S. Manufacturing Footprint With $750 Mln Hillsboro Investment

Genentech (Roche) plans to invest about $750 million to build a new device fill-finish manufacturing facility on its 75-acre Hillsboro, Oregon campus to support production of drug-delivery devices. The capex signals scaling of manufacturing capacity for device-based therapies, a constructive operational step though not an immediate earnings catalyst.

Analysis

Genentech (Roche) plans to invest about $750 million to build a new device fill-finish manufacturing facility on its 75-acre Hillsboro, Oregon campus to support production of drug-delivery devices. The capex signals scaling of manufacturing capacity for device-based therapies, a constructive operational step though not an immediate earnings catalyst.